<pad> C ross-protective efficacy of HPV-16/18 AS04–adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. C ross-protective efficacy of HPV-16/18 AS04–adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. C ross-protective efficacy of HPV-16/18 AS04–adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. C ross-protective efficacy of HPV-16/18 AS04–adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types</s>